QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:CNST

Constellation Pharmaceuticals Stock Forecast, Price & News

$27.22
-9.09 (-25.03 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.32
Now: $27.22
$33.25
50-Day Range
$27.48
MA: $33.18
$37.00
52-Week Range
$17.00
Now: $27.22
$50.90
Volume1.66 million shs
Average Volume482,353 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.8
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Constellation Pharmaceuticals logo

Headlines

CNST Crosses Below Key Moving Average Level
February 24, 2021 |  nasdaq.com
CNST Feb 2021 30.000 call
January 19, 2021 |  uk.finance.yahoo.com
CNST Jan 2021 25.000 put
December 21, 2020 |  uk.finance.yahoo.com
CNST Jan 2021 22.500 put
December 21, 2020 |  uk.finance.yahoo.com
CNST Jan 2021 15.000 put
December 21, 2020 |  uk.finance.yahoo.com
CNST Jan 2021 40.000 put
December 21, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555
Employees106
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$8.23 per share

Profitability

Net Income$-85,550,000.00

Miscellaneous

Market Cap$1.30 billion
Next Earnings Date2/24/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.16 out of 5 stars

Medical Sector

880th out of 1,958 stocks

Pharmaceutical Preparations Industry

435th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$27.22
-9.09 (-25.03 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

Is Constellation Pharmaceuticals a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Constellation Pharmaceuticals stock.
View analyst ratings for Constellation Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Constellation Pharmaceuticals?

Wall Street analysts have given Constellation Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Constellation Pharmaceuticals
.

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) issued its earnings results on Thursday, October, 29th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.03.
View Constellation Pharmaceuticals' earnings history
.

How has Constellation Pharmaceuticals' stock price been impacted by COVID-19?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 16.4% and is now trading at $27.22.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CNST?

8 equities research analysts have issued 12-month price targets for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $46.00 in the next twelve months. This suggests a possible upside of 69.0% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Chief Financial Officer (Age 60, Pay $570.4k)
  • Dr. Adrian M. Senderowicz M.D., Sr. Advisor (Age 57, Pay $605.9k)
  • Dr. Danny Reinberg, Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder
  • Dr. David Allis, Co-Founder
  • Mr. Mohan Bala Ph.D., Chief Operating Officer
  • Dr. Patrick Trojer Ph.D., Sr. VP & Chief Scientific Officer (Age 48)
  • Mr. Ronald Aldridge, Sr. Director of Investor Relations (Age 67)
  • Kia Khaleghpour Ph.D., VP of Investor Relations & Communications

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Avoro Capital Advisors LLC (6.20%), BlackRock Inc. (5.46%), Lord Abbett & CO. LLC (3.54%), Morgan Stanley (2.58%), Jennison Associates LLC (2.49%) and Victory Capital Management Inc. (2.47%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer.
View institutional ownership trends for Constellation Pharmaceuticals
.

Which major investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Avoro Capital Advisors LLC, PFM Health Sciences LP, Regents of The University of California, Price T Rowe Associates Inc. MD, Ghost Tree Capital LLC, SG Americas Securities LLC, P.A.W. Capital Corp, and Credit Suisse AG. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, Group L P Column, James E Audia, Karen Valentine, Mark A Goldsmith, and Patrick Trojer.
View insider buying and selling activity for Constellation Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Constellation Pharmaceuticals stock?

CNST stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Lord Abbett & CO. LLC, BlackRock Inc., Jennison Associates LLC, Victory Capital Management Inc., GSA Capital Partners LLP, Alliancebernstein L.P., and Silverarc Capital Management LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Anthony B Evnin, and Group L P Column.
View insider buying and selling activity for Constellation Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $27.22.

How much money does Constellation Pharmaceuticals make?

Constellation Pharmaceuticals has a market capitalization of $1.30 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Constellation Pharmaceuticals have?

Constellation Pharmaceuticals employs 106 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Where are Constellation Pharmaceuticals' headquarters?

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.